Evogene annual stock-based compensation
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Evogene Stock-Based Compensation Growth & History (EVGN)
Evogene's stock-based compensation was $654,000 for fiscal 2025.
View full Evogene company overviewEvogene annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $654,000 | −$589,000 | −47.39% |
| 2024 | 2024-12-31 | $1.2M | $135,000 | +12.18% |
| 2023 | 2023-12-31 | $1.1M | −$78,000 | −6.58% |
| 2022 | 2022-12-31 | $1.2M | −$1.4M | −54.54% |
| 2021 | 2021-12-31 | $2.6M | −$1.5M | −36.32% |
| 2020 | 2020-12-31 | $4.1M | $2.5M | +159.63% |
| 2019 | 2019-12-31 | $1.6M | −$153,000 | −8.84% |
| 2018 | 2018-12-31 | $1.7M | −$513,000 | −22.86% |
| 2017 | 2017-12-31 | $2.2M | −$699,000 | −23.75% |
| 2016 | 2016-12-31 | $2.9M | −$1.4M | −32.58% |
| 2015 | 2015-12-31 | $4.4M | — | — |
Evogene quarterly stock-based compensation
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $93,000 | −$126,000 | −57.53% |
| Q1 2026 | 2026-03-31 | −$9,000 | −$247,000 | — |
| Q4 2025 | 2025-12-31 | $155,000 | — | — |
| Q3 2025 | 2025-09-30 | $27,000 | — | — |
| Q2 2025 | 2025-06-30 | $219,000 | — | — |
| Q1 2025 | 2025-03-31 | $238,000 | — | — |
Evogene stock-based compensation trends
Over the last five fiscal years, Evogene's stock-based compensation decreased from $4.1M to $654,000, a change of −$3.4M. The latest reported quarter, Q2 2026, shows $93,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Evogene source filings ↗